Skip to main content
Caplight Logo









Umoja Biopharma

Umoja Biopharma

Private
Seattle, WashingtonHealthcare & Life Scienceshttps://www.umoja-biopharma.com/

Last Round

IPO

Apr 9, 2026

Est. Valuation

$420M

Total Funding Raised

$373M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Umoja Biopharma is a biotechnology company that develops in vivo immunotherapies to reprogram a patient's immune system to fight cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

in vivo CAR-TimmunotherapyCAR T-cell therapyin vivo gene deliveryin-situ cell therapyoff-the-shelf cell therapygene therapycancer immunotherapycell engineeringautoimmune disease therapylentiviral vectorclinical-stage biotechVivoVechematologic malignanciesTumorTagRACR/CAR

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Umoja Biopharma Comparables

Compare Umoja Biopharma with similar companies based on industry and business-model similarity.

Umoja Biopharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
CREATE Medicines
83%
AbbVie
81%
Sana Biotechnology
79%

Umoja Biopharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
IPOApr 9, 2026
Series CJan 14, 2025
SeedJan 9, 2024
Series BJun 15, 2021
Series ANov 18, 2020
Seed
Nov 21, 2019

Key People

Founding team and executive leadership

Nate Hardy

Chief Financial Officer

Executive Team

Umoja Biopharma Investors

Notable investors and investment history

Umoja Biopharma investors
InvestorRounds
MPM CapitalSeries B, Seed, Series C, Series A
SoftBank Investment AdvisersSeries C, Series B
TemasekSeries B
DCVC BioSeries B, Seed, Series A, Series C
Cormorant Asset ManagementSeries C, Series B
Psalion VCSeed
Orange DAOSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 9, 2026

    Completed an IPO round of funding.

  • Apr 9, 2026

    Opened a new cell/gene therapy GMP manufacturing facility in Louisville, CO.

Umoja Biopharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Umoja Biopharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Umoja Biopharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range234
Year Founded2019
Last FundingApr 9, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.